Cladribine Tablets as an Exit Therapy Strategy

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Mar 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of Cladribine Tablets (CladT) as a potential last treatment option for older adults with Multiple Sclerosis (MS), specifically those with Relapsing Remitting MS or Secondary Progressive MS. Researchers want to find out if CladT can help keep the disease stable and is safe for patients who have been living with MS for a long time. To participate in this study, patients should be at least 45 years old, have had a diagnosis of Relapsing Remitting MS for more than 10 years, and must not have had any signs of disease activity for at least the last five years while on other treatments.

Those who join the trial can expect to be monitored closely over a minimum of 24 months. Researchers will look at how many patients experience relapses (worsening symptoms), progression of disability, or new problems seen in MRI scans of the brain. This will help determine if CladT is effective in maintaining stability for aging MS patients compared to those who continue or stop their current treatments. The trial is currently not recruiting participants, and it’s important to note that individuals with more severe forms of MS or those not on any disease-modifying treatments are not eligible to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient ≥45-year-old with RRMS
• • Disease duration ≥10 years
• • No evidence of disease activity ≥5 years under DMT
• • EDSS score between 0 and 6.0 included
• Exclusion Criteria:
• • Progressive form of MS
• • Patients without DMT
• • EDSS score ≥6.5